InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.795

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$335 Response to media article 4 Mar 2022 10:00AM $0.890 $0.795 fallen by 10.67%
$335 SPL7013 in VIRALEZE virucidal against Omicron 1 Mar 2022 11:27AM $0.910 $0.795 fallen by 12.64%
$335 Dr Jeff Davies appointed as non-executive director 24 Feb 2022 9:08AM $0.950 $0.795 fallen by 16.32%
$335 Interim Report and Half-Year Financial Results 21 Feb 2022 9:32AM $1.040 $0.795 fallen by 23.56%
$335 VIRALEZE distribution in Saudi Arabia - supplementary info 4 Feb 2022 4:04PM $1.025 $0.795 fallen by 22.44%
$335 Change in substantial holding 4 Feb 2022 8:20AM $1.015 $0.795 fallen by 21.67%
$335 VIRALEZE sales and distribution in Saudi Arabia and GCC 3 Feb 2022 9:31AM $1.065 $0.795 fallen by 25.35%
$335 Application for quotation of securities - SPL 1 Feb 2022 4:24PM $1.050 $0.795 fallen by 24.29%
$335 Application for quotation of securities - SPL 1 Feb 2022 4:20PM $1.050 $0.795 fallen by 24.29%
$335 Notification of cessation of securities - SPL 1 Feb 2022 4:07PM $1.060 $0.795 fallen by 25%
$335 Quarterly Cashflow and Activities Report 28 Jan 2022 10:05AM $0.995 $0.795 fallen by 20.10%
$335 Starpharma receives $7.7M R&D tax incentive refund 20 Jan 2022 8:48AM $1.160 $0.795 fallen by 31.47%
$335 Notification of cessation of securities - SPL 23 Dec 2021 10:52AM $1.330 $0.795 fallen by 40.23%
$335 Shareholder Newsletter 16 Dec 2021 1:22PM $1.315 $0.795 fallen by 39.54%
$335 VIRALEZE antiviral nasal spray registered in Saudi Arabia 14 Dec 2021 9:55AM $1.300 $0.795 fallen by 38.85%
$335 VIRALEZE successfully launched in Vietnam 13 Dec 2021 11:04AM $1.270 $0.795 fallen by 37.40%
$335 US Biopharma DEP Research Agreement - Additional Information 8 Dec 2021 10:06AM $1.200 $0.795 fallen by 33.75%
$335 Starpharma signs DEP Research Agreement with US Biopharma Co 7 Dec 2021 9:08AM $1.145 $0.795 fallen by 30.57%
$335 Change in Director's Interest Notice - J Fairley 3 Dec 2021 2:30PM $1.190 $0.795 fallen by 33.19%
$335 Notification regarding unquoted securities - SPL 3 Dec 2021 2:26PM $1.190 $0.795 fallen by 33.19%
$335 VIRALEZE distribution agreement and launch in Vietnam 3 Dec 2021 9:34AM $1.170 $0.795 fallen by 32.05%
$335 VIRALEZE registered in Vietnam with launch this week 1 Dec 2021 9:28AM $1.085 $0.795 fallen by 26.73%
$335 AGM Results 30 Nov 2021 2:32PM $1.095 $0.795 fallen by 27.40%
$335 AGM Chairman address and CEO presentation 30 Nov 2021 10:07AM $1.045 $0.795 fallen by 23.92%
$335 Positive DEP phase 2 interim results in prostate cancer 25 Nov 2021 11:03AM $1.095 $0.795 fallen by 27.40%

251 - 275 of 867 results

Page 11 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.